Practical guidance for mismatch repair-deficiency testing in endometrial cancer by Stelloo, E, Jansen, A, Osse, E, Nout, R, Creutzberg, C, Church, D, Morreau, H, Smit, V, van Wezel, T, Bosse, T

Prognostic benefit of POLE exonuclease domain mutations in endometrial cancer cannot be explained by increased sensitivity to adjuvant treatment strategies by Van Gool, I, Rayner, E, Osse, E, Tomlinson, I, Smit, V, Creutzberg, C, Church, D, de Wind, N, Bosse, T, Drost, M

Adjuvant treatment for POLE proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues by Van Gool, I, Rayner, E, Osse, E, Nout, R, Creutzberg, C, Tomlinson, I, Church, D, Smit, V, de Wind, N, Bosse, T, Drost, M

POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer by Klenerman, P, Church, D, Tomlinson, I, van Gool, I, Eggink, F, Freeman-Mills, L, Stelloo, E, Marchi, E, de Bruyn, M, Palles, C, Nout, R, de Kroon, C, Osse, E, Creutzberg, C, Smit, V, Nijman, H, Bosse, T